INTRODUCTION

76
High blood pressure is the leading risk factor for global disease burden (1). The maintenance 77 of a healthy blood pressure and the prevention of hypertension continues to be a public health 78 priority worldwide (2, 3) . It is estimated that for every 10 mmHg reduction in systolic blood 79 pressure there is a 13-28% lower risk of cardiovascular disease events and all-cause mortality 80 (4) . Arterial stiffness, which is closely related to hypertension (5, 6) , is also a predictor of 81 cardiovascular and all-cause mortality (7) . Diets rich in vegetables, such as the vegetarian diet suggests that inorganic nitrate found in vegetables can contribute to lowering blood pressure 86 (10, 11) .
87
Inorganic nitrate is a precursor for nitric oxide (NO) (12) . Nitric oxide is an important cell 88 signalling molecule and potent vasodilator critical for vascular health (13) . The enterosalivary 89 nitrate-nitrite-NO pathway generates NO via the sequential reduction of the anions nitrate and 90 nitrite. This is facilitated by facultative anaerobic bacteria in the oral cavity, the acidic 91 environment of the stomach and numerous endogenous molecules identified as having nitrite 92 reducing ability (14) . Increased scavenging of NO and dysfunction of the L-arginine-NO exclusion criteria see Supplemental Hospital, Perth, Australia). Blood pressure was assessed using a Dinamap 1846SX/P 139 oscillometric recorder (Critikon Inc., Tampa, FL, USA). Participants were asked to rest for 5 140 minutes before five blood pressure and heart rate readings were taken at 2 minute intervals.
141
The first measurement was excluded and the mean of the next four consecutive readings was 142 used to determine resting blood pressure. After blood tests confirmed eligibility, participants 143 were asked to return to the research clinic to complete a medical examination by one of our total carotenoids were used to assess compliance.
173
Clinical measurements
174
Anthropometric measurements (body weight, waist circumference, and hip circumference) 175 were assessed pre-and post-treatment. Participants were wearing minimal clothing and no 176 shoes. Standing height (m) was measured without shoes using a wall-mounted stadiometer to 177 the nearest 0.01 m. Fasting body weight (kg) was measured without shoes using electronic 178 scales to the nearest 0.01 kg. Waist and hip circumference (cm) were measured using a steel 179 tap measure (Lufkin Executive Thinline, W606PM, USA). Waist and hip measurements were 180 used to calculate waist-to-hip ratio (waist cm / hip cm).
181
Physical activity was assessed pre-and post-treatment using the validated short form of the
182
International Physical Activity Questionnaire (IPAQ) (25) traces that were missing more than four hourly means over the 24 hours were also excluded 194 from the analysis. A minimum of 70% successful readings was considered a valid recording.
195
Mean blood pressure was determined for the 24-hour, daytime (06:00-21:59), and night-time 
Biochemical analyses
232
Fasting (≥12 hours) blood, saliva, and urine samples were collected pre-and post-treatment. internal standards, as previously described (27) .
243
Plasma carotenoid analysis
244
High-performance liquid chromatography (HPLC) methodology was used to determine 245 plasma carotenoid concentrations of β-carotene, lycopene, α-carotene, β-cryptoxanthin, and 246 lutein/ zeaxanthin, as previously described (28) . Carotenoids were extracted using ethanol, 
Sample size
260
The required sample size for the study was based on the primary outcome of blood pressure 261 measured using 24-hour ambulatory monitoring. It was estimated 25 participants would 262 provide >80% power to detect a 2.0 mmHg difference in mean 24-hour systolic blood 263 pressure, based on data from our previous studies (29, 30) . This calculation assumes a type I 264 error rate of 0.05/3 (0.017). In addition, we had >80% power to detect a 2.0 mmHg difference 265 in mean home systolic blood pressure, based on data from our previous studies (29, 30) .
266
Statistical methods
267
Global statistical significance was set at a 2-sided Type 1 error rate of P<0.05. All data were and treatment order. We tested for any carryover effects between treatment periods using a 277 treatment*treatment period interaction term.
RESULTS
279
Recruitment began on 25 May 2015 and final data was collected on 5 May 2016. Of the 65 280 participants screened for the study, 32 participants were randomised of whom 30 completed 281 the study. Two participants withdrew after randomisation due to medical reasons unrelated to 282 the trial (Figure 1 ).
283
Baseline demographic and clinical characteristics for the 30 participants are shown in Table   284 1. Baseline dietary data is shown in Supplemental (Figure 2) .
321
There was a 1.7-fold increase in plasma nitrate concentrations for the high nitrate treatment 322 compared to the low nitrate treatment (P<0.001) and a 1.6-fold increase for the high nitrate ( Figure 2 ). There was a 1.9-fold increase in urinary nitrate concentration for the high nitrate 
342
Plasma carotenoids
343
Descriptive statistics for plasma total carotenoids, lutein, beta-cryptoxanthin, lycopene, alpha-344 carotene, and beta-carotene are presented in Table 3 . Plasma total carotenoids were 345 significantly different between treatments (P<0.001) (Figure 3 ). There was a 1.4-fold increase and a 1.8-fold increase in the high nitrate treatment compared to the control (P<0.001) ( Figure   351 3). Plasma beta-carotene was significantly different between treatments (P=0.002) (Figure 3 ).
to the control (P=0.002) and a 1.6-fold increase in the low nitrate treatment compared to the 354 control (P=0.003) (Figure 3 ). Plasma beta-cryptoxanthin, lycopene, and alpha-carotene were 355 not significantly different between treatments (Figure 3 ).
356
Plasma and urinary sodium and potassium
357
Plasma and urinary sodium and potassium, and urinary sodium to potassium ratio were not 358 significantly different between treatments ( Table 4) .
359
Blood pressure
360
Ambulatory blood pressure
361
Ambulatory measures of blood pressure were excluded for 2 (6.7%) participants due to 362 equipment malfunction (n=1) and <70% successful readings (n=1). The mean (SD) 24-hour,
363
daytime, and night-time ambulatory measures of blood pressure and heart rate pre-and post-364 treatment are presented in Table 5 . There were no significant differences between treatments 365 for mean 24-hour, daytime, or night-time ambulatory blood pressure and heart rate ( Figure   366 4). No carryover effects were observed for 24-hour, daytime, and night-time ambulatory
367
measures of blood pressure and heart rate (P>0.05 for all). In a post-hoc sensitivity analysis in 368 which we adjusted for age, gender and BMI, the results were very similar and not 369 substantively changed (data not shown).
370
Home blood pressure
371
Home measures of blood pressure were complete for all participants. Mean (SD) home 372 measures of blood pressure and heart rate pre-and post-treatment are presented in Table 5 .
373
There were no significant differences between treatments for blood pressure and heart rate for 374 the last 7 days of treatment ( Figure 4 ). There were also no significant differences between 375 treatments for blood pressure and heart rate for week 1, week 2 and week 3 of treatment when 376 analysed separately ( Figure 5 ). In addition, we found no significant differences between 377 treatments for blood pressure and heart rate measured in the morning, afternoon, and evening when analysed separately (data not shown). Mean daily home measures of blood pressure and 379 heart rate are shown in Supplemental Figure 2 . No carryover effects were observed for 380 home measures of blood pressure and heart rate (P>0.05 for all).
381
Clinic blood pressure
382
Clinic measures of blood pressure were complete for all participants. Mean (SD) clinic 383 measures of blood pressure and heart rate pre-and post-treatment are presented in Table 5 .
384
There were no significant differences between treatments for blood pressure and heart rate 385 ( Figure 4 ).
386
Arterial stiffness
387
Pulse wave analysis was complete for all participants. Pulse wave velocity was incomplete for 388 4 (13.3%) participants due to an inability to obtain measurements. Mean (SD) central systolic Only three studies have investigated the short-term sustained effects of nitrate ingestion on 426 blood pressure and arterial stiffness over a period of four or more weeks (19, 33, 42 likely an outcome of the GCMS method compared to gas phase chemiluminescence (27) . however, utilised for all laboratory analyses. Lastly, we cannot rule out any small effects on 482 blood pressure, less than approximately 2 mmHg.
483
In summary, our findings suggest no short-term clinically significant effects on blood 2 Between-treatment differences are for the post-treatment values of the high nitrate (HN) compared with low nitrate (LN) and control (C) treatments, adjusted for pre-treatment values, treatment period and treatment order using repeated measures mixed modelling. There were no significant differences between treatments. Table 5 . Descriptive statistics for blood pressure by treatment, and the between-treatment differences 2 Between-treatment differences are for the post-treatment values of the high nitrate (HN) compared with low nitrate (LN) and control (C) treatments, adjusted for pre-treatment values, treatment period and treatment order using repeated measures mixed modelling. There were no significant differences between treatments. 3 n=26. systolic blood pressure, (B) diastolic blood pressure, and (C) heart rate for week 1, week 2, and week 3. Results are presented as estimated mean ± SE adjusted for the 7 days prior to pretreatment, treatment period and treatment order using repeated measures mixed modelling (n=30). There were no significant differences between treatments.
